Salvacion USA Inc. – FDA Warning Letter, Feb 20, 2024
On February 13, 2024, the FDA issued a Warning Letter to Mr. Hwang concerning the distribution of Covixyl Nasal Spray. The FDA reviewed the firm's website (https://covixyl.com/) and social media pages (https://twitter.com/gocovixyl, https://www.facebook.com/covixyl) on October 10, 2023.
The FDA determined that Covixyl Nasal Spray is an unapproved new drug, violating sections 505(a) and 301(d) of the Federal Food, Drug, & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). The product is classified as a drug under section 201(g)(1)(B) and/or 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B) and 321(g)(1)(C), due to claims indicating its intended use for disease diagnosis, cure, mitigation, treatment, prevention, or to affect body structure/function.
Examples of violative claims include: "Covixyl® was developed to safely and effectively create a barrier in the nasal passages that helps block airborne viruses, keeping you
ID · 22869b9d-095b-4737-87fc-8f205f47eaf9
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.